Weekly Dosing in Reach?
'Baxter' the Wall: Biogen/Sobi Data Weighed in Hemophilia A
By Randy Osborne
Thursday, November 1, 2012
With safety and efficacy endpoints met in the Phase III trial testing Biogen Idec Inc.'s long-lasting rFVIIIFc (recombinant Factor VIII Fc fusion protein) for hemophilia A, investors were scrutinizing the candidate's odds in a market led by Advate, the serum-free, recombinant Factor VIII therapy from Baxter Healthcare Corp.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.